Literature DB >> 24342797

Opposite regulation of hepatic breast cancer resistance protein in type 1 and 2 diabetes mellitus.

Lei He1, Yuan Yang2, Cen Guo1, Dan Yao3, Hui-hui Liu3, Jing-jing Sheng3, Wei-ping Zhou2, Jin Ren3, Xiao-dong Liu4, Guo-yu Pan5.   

Abstract

Previous studies on diabetes have reported controversial results with regard to transporters in liver. The present study aimed to explore changes in hepatic breast cancer resistance protein (BCRP) expression and functions, as well as the possible underlying mechanisms, in type 2 diabetic patients, type 1 (streptozotocin-induced), and type 2 (Goto Kakizaki) diabetic rats. Protein and mRNA levels of human (h) and rat (r) BCRP were investigated using Western blot and quantitative polymerase chain reaction analyses. Functions of liver rBCRP were evaluated using rosuvastatin. Sandwich cultured rat hepatocytes (SCRH) were cultured with d-glucose, insulin, or oleic acid for 72 h, and rBCRP mRNA was detected. The effect of oleic acid on rBCRP function in SCRH was also investigated using rosuvastatin. Results showed that liver rBCRP mRNA levels decreased to 20% in type 1 diabetic rats, whereas that in diabetic patients and GK rats significantly increased threefold and twentyfold, respectively. No changes were observed in h/rBCRP protein levels of type 2 diabetic patients and GK rats. The functions of rBCRP significantly declined in type 1 diabetic rats but showed no significant changes in GK rats. The data from SCRH indicated that d-glucose decreased rBCRP mRNA level to 60%. Oleic acid increased rBCRP mRNA in SCRH by approximately eightfold but decreased rBCRP function to 50%. Therefore, h/rBCRP expression and functions were oppositely regulated in type 1 and type 2 diabetes mellitus subjects. Alternations in d-glucose, insulin, and free fatty acid levels in plasma might contribute to the changes in h/rBCRP expression and functions.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer resistant protein; D-glucose (PubChem CID: 5793); Diabetes; Oleic acid (PubChem CID: 445639); Rosuvastatin calcium (PubChem CID: 5282455); Sandwich cultured rat hepatocytes

Mesh:

Substances:

Year:  2013        PMID: 24342797     DOI: 10.1016/j.ejphar.2013.12.008

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes.

Authors:  Dan Xu; Feng Li; Mian Zhang; Ji Zhang; Can Liu; Meng-yue Hu; Ze-yu Zhong; Ling-ling Jia; Da-wei Wang; Jie Wu; Li Liu; Xiao-dong Liu
Journal:  Acta Pharmacol Sin       Date:  2014-08-25       Impact factor: 6.150

Review 2.  Sandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury.

Authors:  Kyunghee Yang; Cen Guo; Jeffrey L Woodhead; Robert L St Claire; Paul B Watkins; Scott Q Siler; Brett A Howell; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2016-02       Impact factor: 3.534

Review 3.  Review of Pharmacokinetic Data of Different Drug Classes in Goto-Kakizaki Rats, a Non-obese Model for Type 2 Diabetes Mellitus: Case Studies and Perspectives.

Authors:  Harilal Patel; Poonam Giri; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-04       Impact factor: 2.441

Review 4.  Altered Expression of Transporters, its Potential Mechanisms and Influences in the Liver of Rodent Models Associated with Diabetes Mellitus and Obesity.

Authors:  Leilei Ma; Lei He; Le Wang; Li Li; Xuena Lin; Guoyu Pan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-06       Impact factor: 2.441

5.  The Effect of Albumin on MRP2 and BCRP in the Vesicular Transport Assay.

Authors:  Feng Deng; Noora Sjöstedt; Heidi Kidron
Journal:  PLoS One       Date:  2016-10-05       Impact factor: 3.240

Review 6.  Imbalance of Drug Transporter-CYP450s Interplay by Diabetes and Its Clinical Significance.

Authors:  Yiting Yang; Xiaodong Liu
Journal:  Pharmaceutics       Date:  2020-04-11       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.